Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk

New generics in Canada likely mark the start of a decline in international revenue of semaglutide, the active ingredient in ...

Wegovy pill on track for blockbuster status as Novo Nordisk navigates crowded GLP-1 market

Novo Nordisk (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy is emerging as the central battleground for ...

Novo Nordisk: A Generational Buying Opportunity Ahead Of Q1 Earnings

Novo Nordisk's 50% Wegovy price cut, aims to secure market share and expand the addressable market. Find out why NVO stock is ...

Novo Nordisk weight-loss pill powers profit beat in race to catch Eli Lilly

By Stine Jacobsen and Maggie Fick COPENHAGEN/LONDON, May 6 (Reuters) - Novo Nordisk beat first-quarter profit forecasts and ...

Novo Nordisk’s Ozempic India Price Cut Boosts Obesity Drug Sales

Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts ...

GLP-1 battle heats up between Eli Lilly and Novo Nordisk

BMO Capital Markets Managing Director, BioPharma Equity Research Evan Seigerman joins Julie Hyman on Market Catalyst to ...

Novo Nordisk actively seeking deals to expand pipeline, CEO says

Novo Nordisk ( NVO) is more active scouting for deals than ever before, its CEO Mike Doustdar told CNBC in an interview ...
MarketBeat on MSN

Hims & Hers earnings preview: The Novo Nordisk shift puts GLP-1 strategy in focus

Healthcare stocks have struggled in 2026. With a year-to-date (YTD) loss of about 6%, that corner of the market has been the worst performer among all 11 sectors of the S&P 500 in 2026. While that has ...